

OptiPrep™ Application Sheet C30

Isolation of rat alveolar type II pneumocytes, lymphoid and myeloid cells

- ◆ OptiPrep™ is a 60% (w/v) solution of iodixanol in water, density = 1.32 g/ml
- ◆ To access other Application Sheets referred to in the text return to the Cell Index; key Ctrl “F” and type the C-Number in the Find Box
- ◆ For other pulmonary cell methods see **Application Sheet C29**
- ◆ See **Reference List RC09** for a list of published papers on all pulmonary cells

1. Background

Alveolar (pneumocyte) type II pneumocytes are widely studied because they synthesize and secrete the phospholipid-rich lung surfactant, which lines the air-alveolar interface and prevents alveolar collapse by lowering surface tension at low lung volumes. Isolation of these cells from both adult and foetal lung is an important prerequisite for the culture and study. Viscardi et al [1-6], who successfully developed a Nycodenz® gradient technique, emphasised the importance of the non-toxic, non-invasive properties of this gradient medium and pointed out that although Percoll® gradients had been used previously for purifying these cells, the potentially toxic nature of a polyvinyl-pyrrolidone-coated silica colloid was of considerable concern in studies of their function.

Viscardi et al [1] reported that the purity of type II pneumocytes from adult lung on Nycodenz® gradients was over 80%; very similar figures were obtained from foetal lung tissue. The recovery of these cells from adult lung was over 70%, while for foetal lung this figure was rather lower at 45-50%. Both the purity and the viability of the cells (approx. 97%) from Nycodenz® gradients were considerably higher than that obtained from cells purified by IgG panning. The cells from Nycodenz® gradients moreover had almost four times the plating efficiency. Other workers [7-9] have reported an even higher purity of >90% for the cells from foetal lung tissue. The same gradient system has also been used by Driscoll et al [10,11] and Johnston et al [12].

- ◆ Recently discontinuous iodixanol gradients have been used to purify these cells [13-19]

2. Preparation of cell suspension

The treatment of the lung tissue prior to gradient centrifugation is a complex operation, the detail of which varies from laboratory to laboratory and is outside the scope of this Application Sheet. For detailed information see refs 1 and 7-13. Briefly the preparation of the cell suspension involves five steps:

1. Rats are anaesthetized and heparin injected as an anticoagulant.
2. After tracheostomy the vasculature is perfused with a buffered saline medium such as 140 mM NaCl, 5 mM KCl, 2.5 mM Na₂HPO₄, 10 mM HEPES, 2.0 mM CaCl₂, 1.3 mM MgSO₄, pH 7.4 to remove blood cells [1]. Sometimes this is supplemented with glucose, nystatin and an antibiotic-antimycotic [12].
3. To remove macrophages, the lungs are lavaged several times with 140 mM NaCl, 5 mM KCl, 2.5 mM Na₂HPO₄, 10 mM HEPES, 6 mM glucose, 0.2 mM EGTA, pH 7.4 followed by lavage with the Step 2 buffer [1]. Sometimes the lavage procedure uses the Step 2 buffer (minus divalent cations) followed by Step 2 buffer [12].
4. Partial disaggregation of the cells by lavage with either elastase [1] or pronase [12]
5. After removal of the trachea, the lung tissue is minced in a solution containing DNase I (in Step 2 buffer) and foetal bovine serum and then incubated at 37°C for 5 min in a trypsinizing flask [1].

3. Cell fractionation in Nycodenz®

The following protocol is adapted from ref 1.

3a. Reagents and solutions required (see Note 1)

1. Nycodenz® powder
2. Nycodenz® solvent: 3 mM KCl, 0.3 mM EDTA, 5 mM HEPES-NaOH, pH 7.5 (Solution 1)
3. Working Solution Diluent: 0.75% (w/v) NaCl, 3 mM KCl, 0.3 mM EDTA, 5 mM HEPES-NaOH, pH 7.5 (Solution 2)

3b. Protocol

1. Prepare a 27.6% (w/v) Nycodenz® stock solution in Solution 1. Place 50 ml of Solution 1 in a 150 ml beaker on a magnetic stirrer set at approx. 50°C and add the Nycodenz® in small amounts until dissolved. Allow the solution to cool to room temperature and then make up to 100 ml with Solution 1. Filter sterilize if required.
2. Dilute the Nycodenz stock solution with Solution 2 to produce 4.6% (w/v) Nycodenz® solution for a continuous gradient or three solutions of 20.7%, 13.8% and 4.6% Nycodenz® for a discontinuous gradient (see Note 2).
3. Filter the lung tissue (in approx 25 ml buffer) sequentially through 2- and 4-ply cotton gauze, followed by 100-, 37- and 15-µm nylon mesh.
4. Dilute with cell suspension buffer to 50 ml and centrifuge at 130 g for 10 min (see Note 3).
5. Suspend the cell pellets in DMEM containing 2% foetal bovine serum.
6. Produce a continuous Nycodenz® gradient of 1.03-1.15 g/ml using a two-chamber gradient maker or a Gradient Master™ using 4 ml each of the 27.6% and 4.6% Nycodenz® solutions.
7. **Alternatively** produce a discontinuous gradient from 2 ml each the 27.6%, 20.7%, 13.8% and 4.6% Nycodenz® solutions (see Step 2) by underlayering from a syringe and metal cannula and allow a continuous gradient to form by diffusion (see Notes 4 and 5).
8. Layer 3 ml of the cell suspension (approx 1×10^7 cells/ml) on top of the gradient.
9. Centrifuge at 1500 g for 20 min at 15°C.
10. Harvest the band of cells (at approx. 1.056 g/ml) just below the sample/gradient interface (see Note 6).

Keep the following stock solutions at 4°C
100 mM HEPES (free acid): 2.38 g per 100 ml water; adjust to pH 7.4 with 1 M NaOH before making up to final volume.

100 mM EDTA (Na₂•2H₂O) 3.72 g per 100 ml water
1 M KCl: 7.46 g per 100 ml water

Solution 1: To 50 ml of water add 5 ml of the HEPES stock solution and 0.3 ml of both the KCl and EDTA stock solutions; adjust to pH 7.4 and make up to 100 ml with water

Solution 2: Dissolve 0.75 g NaCl in 50 ml of water; add 5 ml of the HEPES stock solution and 0.3 ml of both the KCl and EDTA stock solutions; adjust to pH 7.4 and make up to 100 ml with water

4. Cell fractionations using OptiPrep™

4a Separation of Alveolar Type II cells

In recent publications [13-28] a simple two layer gradient of iodixanol of densities 1.040 and 1.080 g/ml was described for the partial purification of Type II alveolar cells from human lung tissue prior to further purification by negative selection with magnetic beads. As iodixanol is available as a sterile solution of density 1.32 g/ml (OptiPrep™) it considerably simplifies gradient solution preparation. If an ordinary balanced salt or buffered saline solution is used to dilute the OptiPrep™, then these two densities are equivalent to approx 6.5% and 14% (w/v) iodixanol, i.e. OptiPrep™:diluent ratios of 6.5:53.5 and 14:46.

4b Separation of mononuclear/lymphoid/haematopoietic type cells

The separation of myeloid and lymphoid cells has also been achieved using a two-layer iodixanol gradient of 4% and 14.5% (w/v), centrifuged at 600 g for 20 min [29]. This gradient was also used to separate haematopoietic cells [30].

Leukocytes (mononuclear cells) from lung tissue have been separated on a 1.079 g/ml barrier prepared from OptiPrep™ (diluted with RPMI containing 10% FCS) [31,32].

5. Notes

1. As all of the solutions used are isoosmotic, it is highly likely that iodixanol can be substituted for Nycodenz® in the methods in Section 3; certainly its availability as a sterile 60% (w/v) solution (OptiPrep™) would make solution preparation much easier. OptiPrep™ would simply be diluted with a suitable buffered saline to the same % (w/v) iodixanol as the Nycodenz® % (w/v). **See Application Sheet C01 for more information.**
2. See Steps 6 and 7 for information about choice of gradient solution preparation.
3. This pelleting step is sometimes carried out at higher g-forces, e.g. 500 g [12]
4. Metal “filling” cannulas can be obtained from any hospital supplies company.
5. If the tube is capped and carefully rotated to a horizontal position, diffusion to form a linear gradient will occur in about 1 h at room temperature. If the tube is maintained in a vertical position this process will take at least 6 h. It is always advisable to check that the density gradient is linear by unloading the gradient in a series of equal volume fractions and determining their density by measuring the refractive index or absorbance. For more information about the preparation gradients see ref 29 **and Application Sheet C02.**
6. The broad band at approx. 1.086 g/ml contains fibroblasts, endothelial cells and macrophages, while any erythrocytes band close to the bottom of the gradient.

6. References

1. Viscardi, R. M., Ullsperger, S. and Resau, J. H. (1992) *Reproducible isolation of Type II pneumocytes from fetal and adult rat lung using Nycodenz gradients* Exp. Lung Res., **18**, 225-245
2. Viscardi, R.M. and McKenna, M.C. (1993) *Developmental changes in cholinephosphate cytidylyl-transferase activity and microsomal phospholipid fatty acid composition in alveolar type II cells* Life Sci., **54**, 1411-1421
3. Viscardi, R.M. and Strauss, K. (1996) *Phospholipid transfer activities are enriched in cytosolic fractions of freshly isolated type II cells (TII) compared with whole lung* Pediatr. Res., **39**, Suppl. 2:354
4. Viscardi, R.M. and Strauss, K. (1996) *Role of phosphatidylinositol transfer protein in type II pneumocytes: regulation of choline phosphate cytidylyltransferase* Pediatr. Res., **39**, Suppl. 2:355
5. Viscardi, R.M., Strauss, K. and Hasday, J.D. (1997) *Oleic acid stimulates rapid translocation of cholinephosphate cytidylyltransferase in type II cells* Biochim. Biophys. Acta, **1349**, 157-170
6. Viscardi, R.M. and Strauss, K.A. (1999) *Developmental changes in phosphatidylinositol transfer protein concentration and phospholipid transfer activities in rat type II cells* Exp. Lung Res., **25**, 561-576
7. Torday, J. S., Sun, H. and Qin, J. (1998) *Prostaglandin E₂ integrates the effects of fluid distension and glucocorticoid on lung maturation* Am. J. Physiol. Lung Cell. Mol. Physiol., **274**, L106-L111
8. Schultz, C. J., Torres, E., Londos, C. and Torday, J. S. (2002) *Role of adipocyte differentiation-related protein in surfactant phospholipids synthesis* Am. J. Physiol. Lung Cell. Mol. Physiol., **283**, L288-L296
9. Torday, J. S. (2003) *Parathyroid hormone-related protein is a gravisensor in lung and bone cell biology* Adv. Space Res., **32**, 1569-1576
10. Driscoll, K. E., Deyo, L. C., Howard, B. W., Poynter, J. and Carter, J. M. (1995) *Characterizing mutagenesis in the hprt gene of rat alveolar epithelial cells* Exp. Lung Res., **21**, 941-956
11. Driscoll, K. E., Deyo, L. C., Carter, J. M., Howard, B. W., Hassenbein, D. G. and Bertram, T. A. (1997) *Effects of particle exposure and particle-elicited inflammatory cells on mutation in rat alveolar epithelial cells* Carcinogenesis, **18**, 423-430
12. Johnston, C. J., Driscoll, K. E., Finkelstein, J. N., Baggs, R., O'Reilly, M. A., Carter, J., Gelein, R. and Oberdorster, G. (2000) *Pulmonary chemokine and mutagenic responses in rats after subchronic inhalation of amorphous and crystalline silica* Toxicol. Sci., **56**, 405-413
13. Manzer, R., Wang, J., Nishina, K., McConville, G. and Mason, R.J. (2006) *Alveolar epithelial cells secrete chemokines in response to IL-1 β and lipopolysaccharide but not to ozone* Am. J. Respir. Cell Mol., **34**, 158-166
14. Wang, J., Edeen, K., Manzer, R., Chang, Y., Wang, S., Chen, X., Funk, C.J., Cosgrove, G.P., Fang, X. and Mason, R.J. (2007) *Differentiated human alveolar epithelial cells and reversibility of their phenotype in vitro* Am. J. Respir. Cell Mol. Biol., **36**, 661-668
15. Mossel, E.C., Wang, J., Jeffers, S., Edeen, K.E., Wang, S., Cosgrove, G.P., Funk, C.J., Manzer, R., Miura, T.A., Pearson, L.D., Holmes, K.V. and Mason, R.J. (2008) *SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells* Virology, **372**, 127-135

16. Miura, T.A., Wang, J., Holmes, K.V. and Mason, R.J. (2007) *Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines* Virology, **369**, 288-298
17. Wang, J., Oberley-Deegan, R., Wang, S., Nikrad, M., Funk, C.J., Hartshorn, K.L. and Mason, R.J. (2009) *Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN- λ 1) in response to influenza A infection* J. Immunol., **182**, 1296-1304
18. Kosmider, B., Loader, J.E., Murphy, R.C. and Mason, R.J. (2010) *Apoptosis induced by ozone and oxysterols in human alveolar epithelial cells* Free Radical Biol. Med., **48**, 1513-1524
19. Ito, Y. and Mason, R.J. (2010) *The effect of interleukin-13 (IL-13) and interferon- γ (IFN- γ) on expression of surfactant proteins in adult human alveolar type II cells in vitro* Respir. Res., **11**, 157
20. Yu, W.C.L., Chan, R.W.Y., Wang, J., Travanty, E.A., Nicholls, J.M., Peiris, J.S.M., Mason, R.J. and Chan, M.C.W. (2011) *Viral replication and innate host responses in primary human alveolar epithelial cells and alveolar macrophages infected with influenza H5N1 and H1N1 viruses* J. Virol., **85**, 6844-6855
21. Kosmider, B., Messier, E.M., Chu, H.W. and Mason, R.J. (2011) *Human alveolar epithelial cell injury induced by cigarette smoke* PLoS One **6**: e26059
22. Messier, E.M., Bahmed, K., Tuder, R.M., Chu, H.W., Bowler, R.P. and Kosmider, B. (2013) *Trolox contributes to Nrf2-mediated protection of human and murine primary alveolar type II cells from injury by cigarette smoke* Cell Death Dis., **4**: e573
23. Goetzman, E.S., Alcorn, J.F., Bharathi, S.S., Uppala, R., McHugh, K.J., Kosmider, B., Chen, R., Zuo, Y.Y., Beck, M.E., McKinney, R.W., Skilling, H., Suhrie, K.R., Karunanidhi, A., Yeasted, R., Otsubo, C., Ellis, B., Tyurina, Y.Y., Kagan, V.E., Mallampalli, R.K. and Vockley, J. (2014) *Long-chain acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction* J. Biol. Chem., **289**, 10668-10679
24. Ito, Y., Correll, K., Schiel, J.A., Finigan, J.H., Prekeris, R., and Mason, R.J. (2014) *Lung fibroblasts accelerate wound closure in human alveolar epithelial cells through hepatocyte growth factor/c-Met signaling*. Am. J. Physiol. Lung Cell. Mol. Physiol., **307**, L94-L105, 2014
25. Ito, Y., Correll, K., Zemans, R.L., Leslie, C.C., Murphy, R.C., Mason, R.J. (2015) *Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF- α /EGFR signaling* Am. J. Physiol. Lung Cell Mol. Physiol. **308**: L1178-L1188
26. Epa, A.P., Thatcher, T.H., Pollock, S.J., Wahl, L.A., Lyda, E., Kottmann, R.M., Phipps, R.P. and Sime, P.J. (2015) *Normal human lung epithelial cells inhibit transforming growth factor- β induced myofibroblast differentiation via prostaglandin E2* PLoS One, **10**: e0135266
27. Xie, W., Wang, H., Liu, Q., Li, Y., Wang, J., Yao, S. and Wu, Q. (2016) *ResolvinD1 reduces apoptosis and inflammation in primary human alveolar epithelial type 2 cells* Lab. Invest., **96**, 526-536
28. Zemski Berry, K. A., Murphy, R.C., Kosmider, B. and Mason, R.J. (2017) *Lipidomic characterization and localization of phospholipids in the human lung* J. Lipid Res., **58**, 926-933
29. Ledford, J.G., Goto, H., Potts, E.N., Degan, S., Chu, H.W., Voelker, D.R., Sunday, M.E., Cianciolo, G.J., Foster, W.M. Kraft, M. and Wright, J.R. (2009) *SP-A preserves airway homeostasis during mycoplasma pneumoniae infection in mice* J. Immunol., **182**, 7818-7827
30. Holmer, S.M., Evans, K.S., Asfaw, Y.G., Saini, D., Schell, W.A., Ledford, J.G., Frothingham, R., Wright, J.R., Sempowski, G.D. and Perfect, J.R. (2014) *Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis* Infect. Immun., **82**, 83-693
31. Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Tatura, A., Heise, M. and Baric, R.S. (2011) *A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge* J. Virol., **85**, 12201-12215
32. Akbay, E.A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J.H., Christensen, C.L., Mikse, O.R., Cherniack, A.D., Beauchamp, E.M., Pugh, T.J. et al. (2013) *Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors* Cancer Discov., **3**, 1355-1363